|
Volumn 374, Issue 21, 2016, Pages 2001-2003
|
Seamless oncology-drug development
a,b a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINEOPLASTIC AGENT;
MONOCLONAL ANTIBODY;
PEMBROLIZUMAB;
CLINICAL TRIAL (TOPIC);
DRUG APPROVAL;
DRUG DEVELOPMENT;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
NEOPLASMS;
ORGANIZATION AND MANAGEMENT;
STANDARDS;
THERAPEUTIC RESEARCH;
UNITED STATES;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS AS TOPIC;
DRUG APPROVAL;
DRUG DISCOVERY;
HUMANS;
NEOPLASMS;
THERAPEUTIC HUMAN EXPERIMENTATION;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
EID: 84971315370
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMp1603747 Document Type: Review |
Times cited : (91)
|
References (5)
|